Impact of adjuvant endocrine therapy utilization in male patients with early breast cancer: results from a large German real-world claims data analysis
Male breast cancer (BC) is a rare entity and represents a significant clinical challenge due to its late diagnosis and resulting poorer prognosis compared to female BC. As shown by prior studies, approximately 99% of male BC patients are hormone receptor-positive (HR +). This study aimed to evaluate...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
17 October 2025
|
| In: |
Archives of gynecology and obstetrics
Year: 2025, Volume: 312, Issue: 6, Pages: 2123-2129 |
| ISSN: | 1432-0711 |
| DOI: | 10.1007/s00404-025-08198-x |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00404-025-08198-x Resolving-System, kostenfrei: https://doi.org/10.1007/s00404-025-08198-x Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s00404-025-08198-x |
| Author Notes: | Dominik Dannehl, Tjeerd Maarten Hein Dijkstra, Alexandra von Au, Anna Sophie Scholz, Léa Louise Volmer, Markus Hahn, Sabine Hawighorst-Knapstein, Ariane Chaudhuri, Florin-Andrei Taran, Markus Wallwiener, Armin Bauer, Diethelm Wallwiener, Sara Yvonne Brucker, Stephanie Wallwiener, Andreas Hartkopf, Tobias Engler |
| Summary: | Male breast cancer (BC) is a rare entity and represents a significant clinical challenge due to its late diagnosis and resulting poorer prognosis compared to female BC. As shown by prior studies, approximately 99% of male BC patients are hormone receptor-positive (HR +). This study aimed to evaluate the utilization and impact of adjuvant endocrine therapy (ET) in male early BC patients using a large German real-world claims dataset. |
|---|---|
| Physical Description: | Online Resource |
| ISSN: | 1432-0711 |
| DOI: | 10.1007/s00404-025-08198-x |